Related Experiment Video
Updated: Jun 29, 2025
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
Quality Control of an Isogenic H/N/KRAS-Less Mouse Embryonic Fibroblast Cell Line Panel
1NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Abstract:
Isogenic H/N/KRAS-less mouse embryonic fibroblast (MEF) cell lines have been developed to assist in cell-based assays of RAS inhibitors. The quality control assessment of a panel of these isogenic MEFs is described here, with a focus on ensuring the proper insertion of the desired mutant RAS transgene, a determination of gene copy number, and an investigation of potential off-target mutations which could lead to phenotypes which are undesired in downstream experiments. Using this suite of quality control tools, a MEF cell line can be readily validated, and researchers can be assured of the rationale for an observed phenotype.
Insights
Quality control methods were developed for isogenic mouse embryonic fibroblast (MEF) cell lines used in RAS inhibitor studies. These methods ensure accurate mutant RAS transgene insertion and identify off-target mutations for reliable experimental results.
Area of Science:
- Cell Biology
- Molecular Biology
- Genetics
Background:
- Isogenic mouse embryonic fibroblast (MEF) cell lines lacking H/N/KRAS are crucial for studying RAS inhibitors.
- Ensuring the genetic integrity of these cell lines is vital for the validity of downstream experiments.
Purpose of the Study:
- To describe a quality control (QC) assessment for isogenic MEF cell lines.
- To validate the proper insertion of mutant RAS transgenes.
- To investigate potential off-target mutations and determine gene copy number.
Main Methods:
- Development and application of a suite of QC tools for MEF cell lines.
- Assessment of mutant RAS transgene insertion.
- Determination of gene copy number.
- Investigation of off-target mutations.
Main Results:
- A comprehensive QC strategy for isogenic MEFs was established.
- Methods confirmed the correct integration of desired mutant RAS transgenes.
- Gene copy number and potential off-target mutations were characterized.
Conclusions:
- The described QC tools enable reliable validation of isogenic MEF cell lines.
- Researchers can confidently interpret experimental phenotypes derived from these validated cell lines.
- This ensures the scientific rationale behind observed results in RAS inhibitor research.
